Journal profile · Multiple
Molecular Therapy Oncology
ISSN 2950-3299 · Elsevier
Molecular Therapy Oncology: CAS Zone 2 · Medicine (2026 Xinrui edition); impact factor 5.3 (journal website); fully open access; APC about USD 3,900; median 159 days to acceptance (65 articles, last 24 months); 167 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Molecular Therapy Oncology is published by Elsevier and is classed under Medicine in the CAS Journal Ranking. By OpenAlex counts of its recent articles, its largest topics are CAR-T cell therapy research, Virus-based gene therapy research and Immunotherapy and Immune Responses, together about 45.7% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Molecular Therapy Oncology is an international, online-only, open-access journal focusing on the development and testing of cancer therapies in pre-clinical and clinical settings. While providing a unique forum for work in the burgeoning fields of biologic cancer therapies including viral, bacterial, cellular, and gene therapy, the journal will consider all top-quality, cutting-edge research that employs innovative approaches to cancer treatment. The scope also encompasses the identification and validation of predictive biomarkers of response. Because the journal is focused on cancer therapies, most accepted papers will have translational relevance. Molecular Therapy Oncology's 2024 impact factor is 5.3.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Main research topics OpenAlex counts of recent articles; shares are approximate
- CAR-T cell therapy researchMedicine20.5%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology16.9%
- Immunotherapy and Immune ResponsesImmunology and Microbiology8.3%
- Immune Cell Function and InteractionImmunology and Microbiology7.3%
- Cancer Research and TreatmentsBiochemistry, Genetics and Molecular Biology6.6%
- Cancer Immunotherapy and BiomarkersMedicine4.3%
- Viral Infectious Diseases and Gene Expression in InsectsBiochemistry, Genetics and Molecular Biology4.2%
- Monoclonal and Polyclonal Antibodies ResearchMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
| Minor | Medicine, Research & Experimental | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2024
- 5.3Publisher website ·
- CiteScore 2026-06
- 9.6LetPub ·
- CiteScore (publisher)
- 9.6Publisher website ·
- SJR 2026-06
- 1.79LetPub ·
- SNIP 2026-06
- 0.92LetPub ·
- h-index
- 15OpenAlex ·
- i10-index
- 46OpenAlex ·
- 2-year mean citedness
- 2.82OpenAlex ·
- Self-citation rate
- 2.4%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 135LetPub ·
Articles by year OpenAlex count · 528 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 210 | 210 | 46 |
| 2025 | 167 | 167 | 412 |
| 2024 | 151 | 151 | 1,030 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
159 daysMedian, submission to acceptance · P25–P75 113 days – 217 days
- Acceptance to online
- median 2 days (65 articles)
- Submission to online
- median 162 days
- Sample
- 65 articles with submission and acceptance dates (422 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Submission to acceptance
- 136 daysPublisher website ·
- Submission to publication (journal-reported)
- about 23 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,900 | Yes | CC BY, CC BY-NC-ND | |
| OpenAlex | USD 3,900 / EUR 3,610 / GBP 3,120 / JPY 483,720 | — | — | |
| Publisher website | USD 3,900 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 3,900 (excluding taxes).
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 2950-3299
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
FAQ
Frequently asked questions about Molecular Therapy Oncology
What CAS zone is Molecular Therapy Oncology in?
In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Therapy Oncology?
The journal's website gives an impact factor of 5.3 (2024); this is the journal's own figure, as LetPub lists none for it; CiteScore 9.6, h-index 15.
How long does peer review take at Molecular Therapy Oncology?
Based on the dates recorded on 65 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 159 days (interquartile range 113–217 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Molecular Therapy Oncology?
According to LetPub and DOAJ records, Molecular Therapy Oncology is indexed in SCIE, Scopus and DOAJ.
Is Molecular Therapy Oncology open access, and what is the APC?
Molecular Therapy Oncology is a fully open-access journal. APC about USD 3,900.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .